Overview
Relay Therapeutics Q3 net loss was $74.15 mln, slightly missing analyst expectations
Operating expenses decreased due to strategic cost-cutting measures
Company advances RLY-2608 trials and appoints two new board members
Approximately $596 million in cash, cash equivalents and investments at end of Q3 2025
Outlook
Company expects cash reserves to fund operations into 2029
Result Drivers
CLINICAL TRIAL EXECUTION - Continued advancement of RLY-2608 trials in breast cancer and vascular malformations contributed to increased costs
COST MANAGEMENT - Strategic choices to streamline research and decrease stock compensation expenses reduced operating costs
R&D EXPENSES: Research and development expenses were $68.3 million for the third quarter of 2025, as compared to $76.6 million for the third quarter of 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.43 | ||
Q3 Net Income | Slight Miss* | -$74.15 mln | -$73.90 mln (7 Analysts) |
Q3 Basic EPS | -$0.43 | ||
Q3 Operating Expenses | $80.39 mln | ||
Q3 Operating Income | -$80.39 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Relay Therapeutics Inc is $14.50, about 54.8% above its November 5 closing price of $6.55
Press Release: ID:nGNX4BzqLv
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)